The investment bank said Q1 sales of Apellis’s drug Syfovre beat the consensus estimate ... granted permanent J-code and likely 2H24 label expansion to include two-year data.” ...

While the company’s topline expanded ~78% to $196.8M, it still missed Wall Street forecasts by $2.99M as Syfovre net product ...

According to the analyst, Syfovre presents a more attractive efficacy profile and a more advantageous label, permitting monthly or bi-monthly dosing and treatment beyond 12 months (although the ...

An online forum where users post images and feedback. Originating in Japan, image boards cover numerous topics, each subject known as a "board." Image boards may have "chan" in their title such as ...

While Syfovre’s revenue miss is no doubt disappointing, the drug remained the market leader in GA with more than 88,500 doses delivered to physicians in the third quarter, Apellis said in its ...

“The third quarter was marked by continued progress, including growth in SYFOVRE vial demand and the positive Phase 3 VALIANT study results in C3G and IC-MPGN. While SYFOVRE net sales fell short ...

The proposed labels are “an obvious and transparent attempt by industry to circumvent California law,” said Howie Hirsch, a retired lawyer in California who has worked on several recycling-related ...

Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in ...

As generative AI image services improve ... Content credentials are like a digital nutrition label you can read to understand the origins of a piece of content. They're a robust kind of digital ...

Much of the growth came from Syfovre, the first Food and Drug Administration (FDA)-approved treatment for eye disorder geographic atrophy (GA). Sales of the drug more than doubled in the third ...